



1644

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p>(to be used for all correspondence after initial filing)</p>		Application Number	09/824,906
		Filing Date	April 2, 2001
		First Named Inventor	Micheal L. GRUENBERG
		Art Unit	1644
		Examiner Name	R. Schwadron
Total Number of Pages in This Submission	10	Attorney Docket Number	549172000113

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply (2 pages) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Revised "Attachment to the Preliminary Amendment Marked Up Paragraphs and Claims (37 CFR 1.121)" (7 pages) 2. Return postcard
<div style="border: 1px solid black; padding: 5px; text-align: center;"> <b>Customer No. 25225</b> </div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Kate H. Murashige - 29,959
Signature	<i>Kate H. Murashige</i>
Date	August 15, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: <u>8/15/03</u>	Signature: <u><i>Michael Boyd</i></u> (Michael Boyd)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 8/15/03

Signature: \_\_\_\_\_

(Michael Boyd)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Micheal L. GRUENBERG

Serial No.: 09/824,906

Filing Date: April 2, 2001

For: AUTOLOGOUS IMMUNE CELL  
THERAPY: CELL COMPOSITIONS,  
METHODS AND APPLICATIONS TO  
TREATMENT OF HUMAN DISEASE

Examiner: R. Schwadron

Group Art Unit: 1644

**RESPONSE TO COMMUNICATION**

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to a communication from the Examiner herein, mailed 18 July 2003, time for response to which was set to expire 18 August 2003. Enclosed is a revised "ATTACHMENT TO THE PRELIMINARY AMENDMENT MARKED UP PARAGRAPHS AND CLAIMS (37 CFR §1.121)" (which accompanied the Response mailed 10/5/01) as requested by the Office, that indicates where brackets have been changed to parentheses on pages 28 and 37.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 549172000113.

Respectfully submitted,

Dated: August 14, 2003

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive,  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125



Applicant: Gruenberg, M.

Serial No.: 09/824,906

Conf. No. 9764

Filed: April 2, 2001

For: **AUTOLOGOUS IMMUNE CELL  
THERAPY: CELL COMPOSITIONS,  
METHODS AND APPLICATIONS TO  
TREATMENT OF HUMAN DISEASE**


Art Unit: 1644

Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, D.C. 20231, on this date.

10/05/01  
Date

  
Kelly Fischer

**ATTACHMENT TO THE PRELIMINARY AMENDMENT  
MARKED UP PARAGRAPHS AND CLAIMS (37 CFR §1.121)**

**IN THE SPECIFICATION:**

**Please amend the paragraph on page 11, lines 3-14, as follows;**

Therefore, it is an object herein to provide such improved methods. In particular, it is an object herein to provide methods for expanding immune cells for use in adoptive immunotherapy protocols without the use of exogenous IL-2. It is also an object herein to provide methods to generate a large array of cell compositions, including compositions containing regulatory cells, for use in adoptive immunotherapy protocols.

It is an object herein to provide means to produce compositions containing clinically relevant numbers of such cells. [he] The availability of a an array of cell compositions permits the design of adoptive immunotherapy protocols for a wide variety of diseases and immune function alterations. Therefore, it is an object herein to provide methods for treating various disorders and altering immune function.

**Please amend the paragraph on page 12, lines 1-8, as follows;**

The compositions of regulatory cells provide a means to alter the immunoregulatory balance of a patient, either locally or [sytemically] systemically, by changing the predominant regulatory cell population. Because